Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy

References

• Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat. Rev. Nephrol.6(12), 711–721 (2011).
   Web of Science ®Google Scholar
• Baron C, Forconi C, Lebranchu Y. Revisiting the effects of CMV on long-term transplant outcome. Curr. Opin. Organ Transplant.15(4), 492–498 (2010).
   PubMedGoogle Scholar
• Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am. J. Transplant.2(9), 850–856 (2002).
   PubMed Web of Science ®Google Scholar
• Reischig T, Jindra P, Svecova M, Kormunda S, Opatrny K Jr, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J. Clin. Virol.36(2), 146–151 (2006).
   PubMed Web of Science ®Google Scholar
• Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation87(3), 436–444 (2009).
   PubMed Web of Science ®Google Scholar
• Smith JM, Corey L, Bittner R et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J. Am. Soc. Nephrol.21(9), 1579–1586 (2010).
   PubMed Web of Science ®Google Scholar
• Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int.66(1), 329–337 (2004).
   PubMed Web of Science ®Google Scholar
• Reischig T. Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies. Expert Rev. Anti Infect. Ther.8(8), 903–910 (2010).
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am. J. Transplant.4(6), 928–936 (2004).
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation89(7), 779–795 (2010).
   PubMed Web of Science ®Google Scholar
• Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant.4(4), 611–620 (2004).
   PubMed Web of Science ®Google Scholar
• Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant.10(5), 1228–1237 (2010).
   PubMed Web of Science ®Google Scholar
• Humar A, Limaye AP, Blumberg EA et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation90(12), 1427–1431 (2010).
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med.340(19), 1462–1470 (1999).
   PubMed Web of Science ®Google Scholar
• Reischig T, Jindra P, Mares J et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation79(3), 317–324 (2005).
   PubMed Web of Science ®Google Scholar
• Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation79(10), 1428–1434 (2005).
   PubMedGoogle Scholar
• Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med.143(12), 870–880 (2005).
   PubMed Web of Science ®Google Scholar
• Shibata D, Martin WJ, Appleman MD, Causey DM, Leedom JM, Arnheim N. Detection of cytomegalovirus DNA in peripheral blood of patients infected with human immunodeficiency virus. J. Infect. Dis.158(6), 1185–1192 (1988).
   PubMed Web of Science ®Google Scholar
• Blok MJ, Christiaans MH, Goossens VJ et al. Evaluation of a new method for early detection of active cytomegalovirus infections. A study in kidney transplant recipients. Transpl. Int.11(Suppl. 1), S107–S109 (1998).
   Google Scholar
• Li H, Dummer JS, Estes WR, Meng S, Wright PF, Tang YW. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J. Clin. Microbiol.41(1), 187–191 (2003).
   PubMed Web of Science ®Google Scholar
• Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant.9(2), 258–268 (2009).
   PubMed Web of Science ®Google Scholar
• Ruttmann E, Geltner C, Bucher B et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation81(10), 1415–1420 (2006).
   PubMed Web of Science ®Google Scholar
• Potena L, Holweg CT, Chin C et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation82(3), 398–405 (2006).
   PubMed Web of Science ®Google Scholar
• Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am. J. Transplant.6(9), 2134–2143 (2006).
   PubMed Web of Science ®Google Scholar
• Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant.8(1), 69–77 (2008).
   PubMed Web of Science ®Google Scholar
• Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am. J. Transplant.8(10), 2111–2118 (2008).
   PubMed Web of Science ®Google Scholar
• Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation81(12), 1645–1652 (2006).
   PubMed Web of Science ®Google Scholar
• Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS ONE4(5), e5512 (2009).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Rivero A, Rodriguez A et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J. Infect. Dis.184(11), 1461–1464 (2001).
   PubMed Web of Science ®Google Scholar
• Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis.46(6), 840–846 (2008).
   PubMed Web of Science ®Google Scholar
• Freeman RB, Paya C, Pescovitz MD et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation78(12), 1765–1773 (2004).
   PubMed Web of Science ®Google Scholar
• Blumberg EA, Hauser IA, Stanisic S et al. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation90(12), 1420–1426 (2010).
   PubMed Web of Science ®Google Scholar
• Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant.8(5), 975–983 (2008).
   PubMed Web of Science ®Google Scholar
• Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation90(4), 412–418 (2010).
   PubMed Web of Science ®Google Scholar
• Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation91(2), 251–255 (2011).
   PubMedGoogle Scholar
• van der Beek MT, Berger SP, Vossen AC et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation89(3), 320–326 (2010).
   PubMed Web of Science ®Google Scholar
• Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant.9(5), 1214–1222 (2009).
   PubMed Web of Science ®Google Scholar
• Weclawiak H, Kamar N, Mengelle C et al. Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients. Transpl. Int.23(10), 1056–1064 (2010).
   PubMedGoogle Scholar
• Gerna G, Lilleri D, Fornara C et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant.6(10), 2356–2364 (2006).
   PubMed Web of Science ®Google Scholar
• Nebbia G, Mattes FM, Smith C et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am. J. Transplant.8(12), 2590–2599 (2008).
   PubMedGoogle Scholar
• Egli A, Binet I, Binggeli S et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J. Transl. Med.6, 29 (2008).
   PubMedGoogle Scholar
• Mattes FM, Vargas A, Kopycinski J et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am. J. Transplant.8(5), 990–999 (2008).
   PubMedGoogle Scholar
• La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J. Infect. Dis.195(5), 633–644 (2007).
   PubMed Web of Science ®Google Scholar
• Tu W, Potena L, Stepick-Biek P et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation114(15), 1608–1615 (2006).
   PubMed Web of Science ®Google Scholar
• Nickel P, Bold G, Presber F et al. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl. Immunol.20(4), 238–242 (2009).
   PubMedGoogle Scholar
• Singh N. Prevention of cytomegalovirus in organ transplant recipients: cross roads between antiviral and antitumor immunity. Transplantation90(4), 360–361 (2010).
   PubMedGoogle Scholar
• Soderberg-Naucler C. Protection from cancer in kidney transplant patients by gammadelta T cells: role of CMV infection? J. Am. Soc. Nephrol.21(1), 11–13 (2010).
   PubMedGoogle Scholar
• Couzi L, Levaillant Y, Jamai A et al. Cytomegalovirus-induced γδ T cells associate with reduced cancer risk after kidney transplantation. J. Am. Soc. Nephrol.21(1), 181–188 (2010).
   PubMed Web of Science ®Google Scholar
• Abate D, Saldan A, Fiscon M et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J. Infect. Dis.202(4), 585–594 (2010).
   PubMed Web of Science ®Google Scholar
• Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation91(8), 927–933 (2011).
   PubMedGoogle Scholar
• Singh N. Unraveling the biologic basis of late-onset cytomegalovirus disease in high-risk organ transplant recipients. Transplantation91(8), 825–826 (2011).
   PubMedGoogle Scholar
• Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J. Clin. Invest.87(6), 1916–1924 (1991).
   PubMed Web of Science ®Google Scholar
• Bowden RA, Digel J, Reed EC, Meyers JD. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J. Infect. Dis.156(6), 899–903 (1987).
   PubMed Web of Science ®Google Scholar
• Battiwalla M, Wu Y, Bajwa RP et al. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol. Blood Marrow Transplant13(7), 765–770 (2007).
   PubMed Web of Science ®Google Scholar
• Reischig T, Prucha M, Sedlackova L et al. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. Antivir. Ther. doi:10.3851/IPM1879 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet365(9477), 2105–2115 (2005).
   PubMed Web of Science ®Google Scholar
• Reischig T, Hribova P, Jindra P et al. Improved long-term renal allograft survival in preemptive valganciclovir therapy compared with valacyclovir prophylaxis for cytomegalovirus: results of randomized controlled trial. Am. J. Transplant.11(Suppl. 2), S455 (2011).
   Google Scholar
• Reischig T, Nemcova J, Vanecek T et al. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Antivir. Ther.15(1), 23–30 (2010).
   PubMed Web of Science ®Google Scholar
• Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis.189(9), 1615–1618 (2004).
   PubMed Web of Science ®Google Scholar
• Myhre HA, Haug Dorenberg D, Kristiansen KI et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation92(2), 217–223 (2011).
   PubMed Web of Science ®Google Scholar
• Couzi L, Helou S, Bachelet T et al. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am. J. Transplant. doi: 10.1111/j.1600-6143.2011.03766.x (2011) (Epub ahead of print).
   Google Scholar
• Hurst FP, Belur P, Nee R et al. Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States Renal Data System. Transplantation92(1), 36–40 (2011).
   PubMed Web of Science ®Google Scholar